通过定量逆转录聚合酶链反应（Q-RTPCR）评估人类肿瘤中核糖核苷酸还原酶（RRM2）M2亚基的信使核糖核酸（mRNA），并通过绝对定量免疫荧光法（AQUA）评估其蛋白质表达。
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
作者信息
Kolesar Jill, Huang Wei, Eickhoff Jens, Hahn Kristine, Alberti Dona, Attia Steven, Schelman William, Holen Kyle, Traynor Anne, Ivy Percy, Wilding George
机构信息
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA.
出版信息
Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86. doi: 10.1007/s00280-008-0845-0. Epub 2008 Oct 22.
Abstract
PURPOSE
The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP.
METHODS
Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA).
RESULTS
Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 +/- 0.94 SD, vs 0.41 +/- 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 +/- 1.49 SD, vs 0.29 +/- 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12).
CONCLUSION
RRM2 gene and protein expression varies by tumor type.
摘要
目的
本研究旨在评估接受3 - 氨基苯甲酰胺（3 - AP）治疗的患者肿瘤中的RRM2蛋白和基因基线表达。
方法
对参与使用3 - AP的I期和II期临床研究的患者的肿瘤组织块，通过定量实时聚合酶链反应（Q - RTPCR）和自动定量分析（AQUA）评估RRM2基因和蛋白表达。
结果
与前列腺癌相比，食管癌和胃癌中RRM2蛋白过表达（Z值分别为0.68±0.94标准差和0.41±0.84标准差；p = 0.04）。与前列腺癌相比，食管癌和胃癌中RRM2 mRNA也过表达（相对基因表达分别为2.56±1.49标准差和0.29±0.20标准差；p = 0.02）。蛋白和基因表达呈中度相关（Spearman等级相关性 = 0.30；p = 0.12）。
结论
RRM2基因和蛋白表达因肿瘤类型而异。
相似文献
1
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86. doi: 10.1007/s00280-008-0845-0. Epub 2008 Oct 22.
2
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mol Oncol. 2020 Aug;14(8):1881-1897. doi: 10.1002/1878-0261.12706. Epub 2020 May 31.
3
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17.
4
Ribonucleotide-diphosphate reductase subunit M2 (RRM2) expression and colorectal cancer invasiveness: a potential prognostic biomarker.
Mol Biol Rep. 2025 May 7;52(1):447. doi: 10.1007/s11033-025-10510-6.
5
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
J Gastroenterol. 2007 May;42(5):389-94. doi: 10.1007/s00535-007-2017-0. Epub 2007 May 25.
6
Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Oncol Rep. 2014 Jun;31(6):2579-86. doi: 10.3892/or.2014.3148. Epub 2014 Apr 23.
7
The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Urol Oncol. 2014 Jan;32(1):51.e9-19. doi: 10.1016/j.urolonc.2013.08.002.
8
Overexpression of catalytic subunit M2 in patients with ovarian cancer.
Chin Med J (Engl). 2012 Jun;125(12):2151-6.
9
Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
Aging (Albany NY). 2022 Oct 3;14(19):7890-7905. doi: 10.18632/aging.204315.
10
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Br J Cancer. 2008 May 20;98(10):1710-5. doi: 10.1038/sj.bjc.6604344. Epub 2008 Apr 15.
引用本文的文献
1
Ribonucleotide-diphosphate reductase subunit M2 (RRM2) expression and colorectal cancer invasiveness: a potential prognostic biomarker.
Mol Biol Rep. 2025 May 7;52(1):447. doi: 10.1007/s11033-025-10510-6.
2
Molecular mechanisms associated with chemoresistance in esophageal cancer.
Cell Mol Life Sci. 2022 Feb 3;79(2):116. doi: 10.1007/s00018-022-04131-6.
3
Common and specific gene signatures among three different endometriosis subtypes.
PeerJ. 2020 Mar 5;8:e8730. doi: 10.7717/peerj.8730. eCollection 2020.
4
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Tumour Biol. 2016 Mar;37(3):3515-26. doi: 10.1007/s13277-015-4175-7. Epub 2015 Oct 9.
5
Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence.
PLoS One. 2015 Apr 15;10(4):e0124366. doi: 10.1371/journal.pone.0124366. eCollection 2015.
6
Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
World J Gastroenterol. 2012 Sep 14;18(34):4704-13. doi: 10.3748/wjg.v18.i34.4704.
7
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Urol Oncol. 2013 Feb;31(2):211-8. doi: 10.1016/j.urolonc.2011.01.002. Epub 2011 Jul 23.
8
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.
Breast Cancer Res. 2010;12(5):R66. doi: 10.1186/bcr2633. Epub 2010 Sep 1.
9
Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells.
J Pineal Res. 2010 Aug;49(1):60-8. doi: 10.1111/j.1600-079X.2010.00767.x. Epub 2010 May 27.
10
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
Cancer Chemother Pharmacol. 2009 May;63(6):1147-56. doi: 10.1007/s00280-008-0890-8. Epub 2008 Dec 13.
本文引用的文献
1
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.
Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):23-30. doi: 10.1097/PAI.0b013e31817c3334.
2
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Invest New Drugs. 2008 Aug;26(4):369-79. doi: 10.1007/s10637-008-9123-6. Epub 2008 Feb 16.
3
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Invest New Drugs. 2007 Dec;25(6):553-8. doi: 10.1007/s10637-007-9066-3. Epub 2007 Jun 22.
4
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.
Clin Cancer Res. 2007 Apr 1;13(7):2207-15. doi: 10.1158/1078-0432.CCR-06-2218.
5
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Invest New Drugs. 2007 Oct;25(5):471-7. doi: 10.1007/s10637-007-9044-9. Epub 2007 Mar 28.
6
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
Anticancer Drugs. 2007 Apr;18(4):377-88. doi: 10.1097/CAD.0b013e328013c04f.
7
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
Oncol Rep. 2006 May;15(5):1299-304.
8
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Br J Cancer. 2004 Aug 2;91(3):482-8. doi: 10.1038/sj.bjc.6602010.
9
Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.
Am J Pathol. 2004 Mar;164(3):831-40. doi: 10.1016/s0002-9440(10)63171-9.
10
Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.
Cancer J. 2003 Jul-Aug;9(4):277-85. doi: 10.1097/00130404-200307000-00010.
Zotero 插件